BioLineRx (BLRX)
(Delayed Data from NSDQ)
$0.45 USD
0.00 (-0.35%)
Updated Nov 7, 2024 03:59 PM ET
After-Market: $0.45 0.00 (-0.31%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.45 USD
0.00 (-0.35%)
Updated Nov 7, 2024 03:59 PM ET
After-Market: $0.45 0.00 (-0.31%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Aclaris Stock Up on JAK Inhibitor's Encouraging Activity
by Zacks Equity Research
Aclaris Therapeutics (ACRS) posts positive interim data from a phase II study on its Alopecia Areata candidate, ATI-502.
BioLineRx Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
BioLineRx Sees Hammer Chart Pattern: Time to Buy?
Shire (SHPG) HAE Drug Gets FDA Nod for Pediatric Population
by Zacks Equity Research
Shire (SHPG) gains FDA approval for expanding the label of its hereditary angioedema (HAE) drug, Cinryze, to include its usage among pediatric patients aged six years and older.
Moving Average Crossover Alert: BioLineRx Ltd. (BLRX)
by Zacks Equity Research
Moving Average Crossover Alert: BioLineRx Ltd. (BLRX)
BioLineRx Cancer Drug Positive as Monotherapy in Phase IIa
by Zacks Equity Research
BioLineRx (BLRX) posts encouraging partial results from the monotherapy portion of a phase IIa COMBAT study, assessing its lead pipeline candidate, BL-8040, for pancreatic cancer patients.
BioLineRx/Roche Scan BL-8040-Tecentriq for Gastric Cancer
by Zacks Equity Research
BioLineRx (BLRX) and partner Genentech initiate a phase Ib/II study to evaluate the company's lead pipeline candidate, BL-8040, in combination with Tecentriq for treating gastric cancer.
BioLineRx Moves a Regulatory Submission for BL-8040 Trial
by Zacks Equity Research
BioLineRx (BLRX) forwards a regulatory submission to begin a phase III study to evaluate BL-8040 in combination with G-CSF for treatment of multiple myeloma.
BioLine Rx (BLRX) Catches Eye: Stock Adds 5.2% in Session
by Zacks Equity Research
BioLine Rx Ltd (BLRX) shares rise over 5% in the last trading session.
BioLineRx/Roche Scan BL-8040-Tecentriq for Pancreatic Cancer
by Zacks Equity Research
BioLineRx Ltd. (BLRX) announced that its partner Genentech, has initiated a phase Ib/II study, evaluating BL-8040 in combination Tecentriq (atezolizumab) for treatment of patients with metastatic pancreatic ductal adenocarcinoma.
BioLineRx Makes Regulatory Submission for Trial of BL-8040
by Zacks Equity Research
BioLineRx Ltd. (BLRX) announced that it has submitted a regulatory filing required to start a phase Ib study for BL-8040 in combination with Roche Group's (RHHBY) Tecentriq (atezolizumab).
BioLineRx (BLRX) Starts Cancer Study on BL-8040+Keytruda
by Zacks Equity Research
BioLineRx (BLRX) announced the initiation of a second phase IIa study on BL-8040 in combination with Keytruda for the treatment of pancreatic cancer.